Tarsus Pharmaceuticals (TARS) Revenue & Revenue Breakdown
Tarsus Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$17.45M
Latest Revenue (Q)
$40.81M
Main Segment (Y)
Product
Tarsus Pharmaceuticals Revenue by Period
Tarsus Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $17.45M | -32.42% |
| 2022-12-31 | $25.82M | -54.73% |
| 2021-12-31 | $57.03M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Tarsus Pharmaceuticals generated $17.45M in revenue during NA 2023, up -32.42% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Tarsus Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $40.81M | 47.80% |
| 2024-03-31 | $27.61M | 111.18% |
| 2023-12-31 | $13.08M | 598.88% |
| 2023-09-30 | $1.87M | -87.75% |
| 2023-06-30 | $15.28M | 511.08% |
| 2023-03-31 | $2.50M | -75.00% |
| 2022-12-31 | $10.00M | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $15.28M | 2734.32% |
| 2022-03-31 | $539.00K | 59.47% |
| 2021-12-31 | $338.00K | -72.74% |
| 2021-09-30 | $1.24M | -94.37% |
| 2021-06-30 | $22.02M | -34.14% |
| 2021-03-31 | $33.43M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Tarsus Pharmaceuticals generated $40.81M in revenue during Q2 2024, up 47.80% compared to the previous quarter, and up 1632.52% compared to the same period a year ago.
Tarsus Pharmaceuticals Revenue Breakdown
Tarsus Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| License Fees and Collaboration | $2.72M | $955.00K | $2.08M |
| Product | $14.73M | - | - |
| Collaboration Revenue | - | $1.92M | $3.96M |
| License and Service | - | $23.89M | $53.07M |
Tarsus Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (84.42%), and License Fees and Collaboration (15.58%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Product | $24.72M | $13.08M | $1.65M | - | - | - | - | - | - | - |
| License And Collaboration | $2.89M | $218.00K | $2.50M | $522.00K | $33.00K | $65.00K | $737.00K | $1.30M | - | - |
| License and Service | - | - | - | - | $10.00M | $13.89M | - | $708.00K | $19.05M | $33.31M |
| Collaboration | - | - | - | - | - | $1.38M | $539.00K | $532.00K | $2.97M | $121.00K |
Tarsus Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (89.52%), and License And Collaboration (10.48%).
Tarsus Pharmaceuticals Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|
| License And Collaboration | $2.50M | $522.00K | $33.00K | $65.00K | $737.00K | $1.30M | - |
| License and Service | - | $10.00M | $13.89M | - | $708.00K | $19.05M | $33.31M |
| Collaboration | - | - | $1.38M | $539.00K | $532.00K | $2.97M | $121.00K |
Tarsus Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 23: License And Collaboration (100.00%).
Tarsus Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TVTX | Travere Therapeutics | $145.24M | $62.90M |
| TRDA | Entrada Therapeutics | $129.01M | $94.69M |
| ETON | Eton Pharmaceuticals | $31.64M | $9.07M |
| GNFT | Genfit | $28.57M | $17.08M |
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| TARS | Tarsus Pharmaceuticals | $17.45M | $40.81M |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| OPT | Opthea | $108.41K | $61.27K |
| DSGN | Design Therapeutics | - | - |
| LIAN | LianBio | - | - |
| ALDX | Aldeyra Therapeutics | - | - |
| NUVL | Nuvalent | - | - |
| PHVS | Pharvaris | - | - |
| RLYB | Rallybio | - | $299.00K |
| CNTB | Connect Biopharma | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| NUVB | Nuvation Bio | - | $1.44M |
| PEPG | PepGen | - | - |
| TYRA | Tyra Biosciences | - | - |
| ELDN | Eledon Pharmaceuticals | - | - |
TARS Revenue FAQ
What is Tarsus Pharmaceuticals’s yearly revenue?
Tarsus Pharmaceuticals's yearly revenue for 2023 was $17.45M, representing a decrease of -32.42% compared to 2022. The company's yearly revenue for 2022 was $25.82M, representing a decrease of -54.73% compared to 2021. TARS's yearly revenue for 2021 was $57.03M, representing an increase of 100.00% compared to 2020.
What is Tarsus Pharmaceuticals’s quarterly revenue?
Tarsus Pharmaceuticals's quarterly revenue for Q2 2024 was $40.81M, a 47.80% increase from the previous quarter (Q1 2024), and a 167.15% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $27.61M, a 111.18% increase from the previous quarter (Q4 2023), and a 1004.56% increase year-over-year (Q1 2023). TARS's quarterly revenue for Q4 2023 was $13.08M, a 598.88% increase from the previous quarter (Q3 2023), and a 30.76% increase year-over-year (Q4 2022).
What is Tarsus Pharmaceuticals’s revenue growth rate?
Tarsus Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -69.41%, and for the last 5 years (2019-2023) was 0%.
What are Tarsus Pharmaceuticals’s revenue streams?
Tarsus Pharmaceuticals's revenue streams in c 23 are License Fees and Collaboration, and Product. License Fees and Collaboration generated $2.72M in revenue, accounting 15.58% of the company's total revenue, up 184.61% year-over-year. Product generated $14.73M in revenue, accounting 84.42% of the company's total revenue
What is Tarsus Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Tarsus Pharmaceuticals was Product. This segment made a revenue of $14.73M, representing 84.42% of the company's total revenue.